A five-dimension evaluation of Arabic-language health websites providing information about HPV and cervical cancer in the arab world: Readability, engagement, usability, accessibility, and quality - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Assessing Arabic-Language Websites on HPV and Cervical Cancer Across the Arab World: Readability, User Engagement, Usability, Accessibility, and Information Quality
Clinical Scorecard: Assessing Arabic-Language Websites on HPV and Cervical Cancer Across the Arab World
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Assessing Arabic-Language Websites on HPV and Cervical Cancer Across the Arab World
Key Mechanisms
Cross-sectional assessment of Arabic-language websites using automated tools to evaluate readability, engagement, usability, and accessibility; experts independently evaluated information quality.
Target Population
Arabic-speaking people seeking online information about HPV and cervical cancer.
Care Setting
Care setting described in the source article.
Key Highlights
The study assessed websites across five dimensions: readability, engagement, usability, accessibility, and information quality.
Search terms were identified through Google Trends and entered into Google, Yahoo, and Bing.
SortSite, Readability Calculator, Similarweb, and WAVE were used for automated assessments.
Experts independently evaluated website information quality.
The article identifies a lack of prior comprehensive assessment of Arabic-language websites covering HPV and cervical cancer.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Not applicable; this is a cross-sectional study of publicly accessible Arabic-language websites, not a treatment study.
No treatments or prescribing outcomes are reported in the provided article content.
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.
